Introduction {#section5-1098612X19857853}
============

Feline hepatic lipidosis (FHL) is considered the most common hepatobiliary disease in cats and is characterised by the accumulation of excessive triglycerides (TGs) in more than 80% of hepatocytes, resulting in liver dysfunction and cholestasis.^[@bibr1-1098612X19857853][@bibr2-1098612X19857853][@bibr3-1098612X19857853]--[@bibr4-1098612X19857853]^ The pathophysiology of FHL is complex and the recent literature has highlighted how FHL results from multiple alterations in the pathways involved in the hepatic uptake of fatty acids (FAs), lipoproteins and glucose, TG degradation and FA oxidation, and lipoprotein secretion in the form of very-low-density lipoproteins.^[@bibr1-1098612X19857853],[@bibr3-1098612X19857853][@bibr4-1098612X19857853]--[@bibr5-1098612X19857853]^ De novo TG synthesis in the liver could cause some of the hepatic FA load and may further exacerbate liver fat accumulation.^[@bibr4-1098612X19857853][@bibr5-1098612X19857853]--[@bibr6-1098612X19857853]^

De novo lipogenesis (DNL) is a complex and highly regulated metabolic pathway.^[@bibr7-1098612X19857853],[@bibr8-1098612X19857853]^ In normal conditions DNL converts excess carbohydrate into FAs, which are then esterified to storage triacylglycerols. The main product of DNL is palmitic acid (C16:0). Palmitic acid can be desaturated by stearoyl-CoA desaturase 1 (SCD-1) to produce palmitoleic acid, or it can be elongated to yield stearic acid (C18:0) and other shorter FAs.^[@bibr8-1098612X19857853][@bibr9-1098612X19857853]--[@bibr10-1098612X19857853]^

In healthy humans, DNL is active in both liver and adipose tissue, whereas in healthy cats the adipose tissue is primarily involved and the liver plays a secondary role. Furthermore, while glucose is the precursor for DNL in humans, in cats the substrate to form the FA palmitate is acetate.^[@bibr3-1098612X19857853],[@bibr11-1098612X19857853][@bibr12-1098612X19857853]--[@bibr13-1098612X19857853]^ DNL is considered to be a minor contributor to lipid formation and lipid homeostasis in healthy individuals.^[@bibr14-1098612X19857853][@bibr15-1098612X19857853][@bibr16-1098612X19857853]--[@bibr17-1098612X19857853]^

However, in humans, hepatic DNL has been demonstrated to contribute to liver steatosis in different metabolic diseases that cause deregulation of the lipogenic pathways, such as obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).^[@bibr18-1098612X19857853][@bibr19-1098612X19857853][@bibr20-1098612X19857853][@bibr21-1098612X19857853]--[@bibr22-1098612X19857853]^

The adipogenic transformation of hepatocytes, with the expression of gene profiles characteristic of healthy adipose tissue, contributes to liver overload with excess free FAs (FFAs).^[@bibr8-1098612X19857853],[@bibr23-1098612X19857853],[@bibr24-1098612X19857853]^ DNL has been demonstrated to contribute up to 26% of FFAs that accumulate in the liver of patients with NAFLD.^[@bibr8-1098612X19857853],[@bibr10-1098612X19857853],[@bibr25-1098612X19857853]^

The role of the molecular mediators of lipogenesis in NAFLD has recently been reviewed.^[@bibr26-1098612X19857853]^

Sterol regulatory element-binding protein 1c (*SREBP-1c*) has been defined as the pivotal controller of lipid biosynthesis and main regulator of the expression of several genes involved in lipogenesis.^[@bibr27-1098612X19857853][@bibr28-1098612X19857853][@bibr29-1098612X19857853]--[@bibr30-1098612X19857853]^ In patients with NAFLD and obese patients, elevated de novo hepatic FA synthesis and secondary TG accumulation in the liver has been reported to be secondary to increased mRNA expression of hepatic *SREBP-1c.* Increasing *SREBP-1c* by inducing lipogenic gene expression, such as those for fatty acid synthase (*FASN*) and peroxisome proliferator-activated receptor gamma (*PPAR-γ*), and suppressing the mRNA expression of peroxisome proliferator-activated receptor alpha (*PPAR-α*), favours hepatic lipogenesis over FA oxidation and leads to steatosis.^[@bibr28-1098612X19857853][@bibr29-1098612X19857853][@bibr30-1098612X19857853][@bibr31-1098612X19857853][@bibr32-1098612X19857853]--[@bibr33-1098612X19857853]^ FASN is involved in conversion of malonyl-CoA into 16-carbon saturated FA palmitate.^[@bibr26-1098612X19857853]^ *PPAR-γ* is required for normal adipocyte differentiation and is expressed at very low levels in the liver of healthy individuals. Overexpression of *PPAR-γ* in the liver leads to hepatic steatosis, also by enhancing the expression of other adipogenic genes in the liver.^[@bibr32-1098612X19857853],[@bibr34-1098612X19857853][@bibr35-1098612X19857853]--[@bibr36-1098612X19857853]^

The physiological significance of DNL in NAFLD has been recently reviewed by Hodson and Frayn.^[@bibr27-1098612X19857853]^ They argued that the most important role of DNL might not be its quantitative contribution to hepatic FA overload, but its part in the suppression of FA oxidation.^[@bibr27-1098612X19857853]^ Malonyl-CoA, a key a metabolic intermediate in de novo FA biosynthesis in lipogenic tissues, is, in fact, a potent inhibitor of the mitochondrial outer membrane enzyme carnitine-palmitoyl transferase 1 (CPT-1).^[@bibr37-1098612X19857853]^ CPT-1 is responsible for the transport of fatty acyl-CoA into the mitochondrion, a fundamental step in FA oxidation.^[@bibr38-1098612X19857853]^ The increased expression of *SREBP-1c* in NAFLD suppresses *PPAR-α*, further inhibiting CPT-1 and FA beta-oxidation.^[@bibr31-1098612X19857853]^

The role of DNL in the development of hepatic lipidosis has been evaluated in the American mink (*Neovison vison*), an obligated carnivore often used as an experimental animal model for NAFLD.^[@bibr12-1098612X19857853],[@bibr13-1098612X19857853]^ These animals share physiological similarities with the domestic cat and they can easily develop hepatic lipidosis after a short period of anorexia.^[@bibr4-1098612X19857853],[@bibr5-1098612X19857853],[@bibr13-1098612X19857853],[@bibr39-1098612X19857853]^ In a recent study evaluating mRNA expression of lipogenic genes in the liver of mink with hepatic lipidosis, Rouvinen-Watt et al confirmed that liver steatosis is partially secondary to the activation of the hepatic DNL.^[@bibr13-1098612X19857853]^

The concept that hepatic DNL could contribute to liver FA overload in cats with hepatic lipidosis was, for the first time, introduced by Hall et al in their study on the lipid composition of hepatic and adipose tissue in cats with FHL.^[@bibr40-1098612X19857853]^ The FA composition of visceral adipose tissue and of the liver of cats with HL revealed greater percentages of palmitate and monounsaturated FAs (MUFAs) than in healthy controls. The increased hepatic concentrations of palmitate in cats with HL vs healthy cats supported the hypothesis that some de novo synthesis of FAs occurs both in the liver and adipose tissue of cats with hepatic lipidosis.^[@bibr40-1098612X19857853]^ Furthermore, in FHL, acetate, like other ketone bodies, is increased as a result of a more complex catabolic state that includes increased insulin resistance and decreased tolerance to glucose.^[@bibr5-1098612X19857853],[@bibr11-1098612X19857853],[@bibr41-1098612X19857853]^ The increased acetate in the liver of cats with FHL constitutes a potential excess substrate for hepatic DNL, contributing and worsening hepatic FA overload.

To date, the concept of adipogenic transformation of hepatocytes and its contribution to hepatic FA accumulation has not been adequately evaluated in cats.

The aim of the present study was to evaluate adipogenic transformation of hepatocytes and de novo lipid synthesis by determination of lipogenic gene expression of *PPAR-α, PPAR-γ, FASN* and *SREBF1* (equivalent in function to *SREBP-1c*) using quantitative RT-PCR (qRT-PCR) in the liver tissue of cats with FHL.

Materials and methods {#section6-1098612X19857853}
=====================

This study was approved by the Committee for the Ethical Care of Animals of Utrecht University. Written, informed consent was obtained from all cat owners prior to study enrolment of the cats.

Animals {#section7-1098612X19857853}
-------

Cats admitted from January 2014 to January 2015 to the Department of Clinical Science of Companion Animals (DCSCA) of the Faculty of Veterinary Medicine, Utrecht University diagnosed with HL based on clinical signs (anorexia, vomiting and icterus), ultrasonography findings (diffuse echodensity of the liver) and cytological evaluation of fine-needle aspirates of the liver consistent with FHL were considered for the study. Only cats that were euthanased owing to deterioration of their clinical condition, despite intense treatment and/or because of financial constraints, were enrolled in the study.

In cats with FHL, wedge liver biopsies were immediately collected post mortem via laparotomy. The biopsies were rinsed in normal saline (NaCl 0.9%), rapidly frozen in liquid nitrogen and then stored at −80°C. These frozen biopsy specimens were used to perform qRT-PCR.

Aged-matched liver biopsies of eight healthy cats were used as controls. These liver biopsies were retrieved from surplus material from a study on the effect of administration of vitamin A on skeletal and hepatic tissue as part of the university's 3R-policy.^[@bibr42-1098612X19857853]^ Good health in these cats was based on a normal physical examination and haematological, biochemical and coagulation parameters within the reference intervals. In this study, percutaneous ultrasound-guided liver biopsies at the beginning and end of the study were taken with a 16 G, 20 cm long biopsy needle (Pro-Mag Biopsy Needle; Argon Medical Devices) under general anaesthesia. The liver biopsies were snap frozen in liquid nitrogen and then stored at −80°C. Only liver biopsies taken at the beginning of the study before supplementation of vitamin A was initiated were used for evaluation of lipogenesis gene expression.

RNA isolation, reverse transcription and quantitative RT-PCR {#section8-1098612X19857853}
------------------------------------------------------------

Total RNA was isolated from liver tissue using a RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. An on-column DNase-I (QIAFEB, RNase-free DNase kit) treatment was included to avoid contamination with residual genomic DNA. RNA concentrations and quality were measured spectrophotometrically using the Nanodrop ND-1000 (Isogen Life Science). RNA integrity was checked on a Bioanalyzer 2100 (Agilent Technologies). The RNA integrity number of all samples exceeded seven. Per sample, at least 3 µg of RNA was used for further processing. cDNA was synthesised from all RNA samples with the iScriptTM cDNA Synthesis Kit (BioRad), which contained both oligo-dT and random hexamer primers to ensure that the cDNA levels were reliably representative of the mRNA levels. Around 600 ng of RNA was incubated with iScript reaction mix, iScript reverse transcriptase and nuclease-free water at 42°C for 30 mins in a 60 μl reaction volume.

As required under MIQE-precise expression stability of the reference genes was evaluated and a combination of ribosomal protein S5 (*RPS5*), β-glucuronidase (*GUSB*) and tyrosine 3-monooxygenase/tryptophan 5-momooxygenase activation protein zeta isoform (*YWHAZ*) was optimal.^[@bibr43-1098612X19857853]^ Primer sequences for specific sequence-confirmed amplicons and optimal annealing temperature are described in [Table 1](#table1-1098612X19857853){ref-type="table"}. The qRT-PCRs were performed in duplicate using the BioRad detection system. Amplifications were carried out in a volume of 25 μl containing 12.5 μl 2 × SYBR green supermix (BioRad), 0.4 µM forward and reverse primer, and 1 μl cDNA and Milli-Q water. Cycling conditions were as follows: denaturation at 95°C for 3 mins, followed by 45 cycles of denaturation (95°C for 10 s) and amplicon-specific annealing temperature for 30 s. A melt curve analysis was performed for every reaction to verify amplicon specificity. IQ5 Real-Time PCR detection system software (BioRad) was used for data analysis. A no template control was also run in duplicate with each plate as a negative control. Expression levels were calculated taken the PCR efficiency into account; the PCR efficiency was always between 96% and 106%.

###### 

Primers for FASN, PPAR-γ, SREBF1 and PPAR-α

![](10.1177_1098612X19857853-table1)

  ------------------------------------------------------------------------------------------
  Gene       Primer 5′ →  3′               Annealing temperature (ºC)   Amplicon size (bp)
  ---------- ----------------------------- ---------------------------- --------------------
  *FASN*     F: GAAATCGGCAAATTCGACCT       65                           115

             R: CTGTTCCCACCTTCATCCA                                     

  *PPAR-γ*   F: TGTGACCTTAACTGTCGTATCC     66--67                       134

             R: CTTCTCTTTCTCCGCCTGTG                                    

  *SREBF1*   F: CGTTTCTTCGTGGATGGG\        63                           140
             R: ACAAATTCAGTGCTGCTC                                      

  *PPAR-α*   F: GACAAATGTGACCGTAGCTG       60                           109

             R: AAACGAATTGCGTTATGGGA                                    

  *RPS5*     F: CAGGTCTTGGTGAATGCG         58                           129

             R: CCAGATGGCCTGATTCAC                                      

  *GUSB*     F: TGACATCACCATCAGCACCAGC     67                           114

             R: GCCTTCCTCATCCAGAAGACGC                                  

  *YWHAZ*    F:GAAGAGTCCTACAAAGACAGCACGC   65                           115

             R: AATTTTCCCCTCCTTCTCCTGC                                  
  ------------------------------------------------------------------------------------------

Sequences based on Kruitwagen et al and Penning et al^[@bibr44-1098612X19857853],[@bibr45-1098612X19857853]^

F = forward; R = reverse

Data are reported as median (range). The Mann--Whitney U-test was used to determine significance for qRT-PCR results between groups, with statistical significance being set at *P* \<0.05.

Results {#section9-1098612X19857853}
=======

Animals {#section10-1098612X19857853}
-------

The FHL group consisted of six client-owned cats (four male castrated, one male intact and one female spayed) that met the inclusion criteria for the study. Three cats were European Shorthairs, two were Maine Coons, one was a Norwegian Forest Cat and one a Turkish Angora. Median age was 4 years and 4 months (range 2--8.5 years) and median body weight was 4 kg (range 3--6.7 kg). Anorexia, lethargy and icterus were the major problems for which 5/6 cats were referred to the DCSCA. One cat was admitted for dyspnoea secondary to chronic traumatic diaphragmatic rupture and developed HL while in hospital.

The control group consisted of six castrated males and two intact males cats. They all were European Shorthair cats. Median age was 4 years and 3 months (range 1.5--7 years) and median body weight was 4.6 kg (range 3--6.3 kg).

Lipogenic gene expression {#section11-1098612X19857853}
-------------------------

In liver tissue, *PPAR-α, PPAR-γ* and *FASN* mRNA expression levels were not significantly different (*P* \>0.12, *P* \>0.89 and *P* \>0.5, respectively) in the FHL group compared with the control group ([Figure 1](#fig1-1098612X19857853){ref-type="fig"}). *SREBF1* gene expression was downregulated around 10-fold in the FHL group vs the control group (*P* = 0.039) ([Figure 1](#fig1-1098612X19857853){ref-type="fig"}).

![Presented are median, first quartile (box) and range (whiskers). Expression per gene is related to the average of the healthy control group, which is set at '1'. Expression corrected for three reference genes *RPS5, GUSB* and *YWHAZ.* \*Only the expression of *SREBF1* is significantly downregulated in feline hepatic lipidosis samples compared with heathy controls](10.1177_1098612X19857853-fig1){#fig1-1098612X19857853}

Discussion {#section12-1098612X19857853}
==========

In humans, in situations of metabolic dysregulation, DNL has been suggested to be abnormally increased and contributes to the pathogenesis of liver steatosis in diseases such as obesity and NAFLD.^[@bibr10-1098612X19857853],[@bibr20-1098612X19857853][@bibr21-1098612X19857853]--[@bibr22-1098612X19857853]^ The increased DNL is characterised by the presence of the FA palmitate, the primary product of de novo FA synthesis, and the MUFA palmitoleic acid, synthesised from palmitate by the action of the enzyme SCD-1.^[@bibr9-1098612X19857853],[@bibr10-1098612X19857853]^

In cats with FHL, a higher concentration of palmitate and MUFAs were found both in the visceral adipose tissue and liver, when compared with healthy cats.^[@bibr40-1098612X19857853]^ This finding was suggestive of an increased DNL in visceral adipose tissue and most likely also in the liver as part of the pathophysiological mechanism of liver steatosis, contributing and worsening FA liver overload.^[@bibr40-1098612X19857853]^

In this study the decrease in liver *SREBF1* gene expression and no expression change in other DNL-related enzymes suggest that DNL does not occur in the liver of cats with FHL. This is in contrast with what has been reported in humans with NAFLD and in other obligated carnivores.^[@bibr13-1098612X19857853],[@bibr18-1098612X19857853][@bibr19-1098612X19857853][@bibr20-1098612X19857853]--[@bibr21-1098612X19857853]^ Furthermore, expression of *PPAR-α* was similar to its expression in healthy cats. This suggests that *CPT-1a* expression and the following degree of β-oxidation in the liver of cats with hepatic lipidosis is not affected by a downregulation of *PPAR-α.*

Using labelled FAs, Donnelly et al concluded that 59% of TGs in the livers of patients with NAFLD were from increased lipolysis in the adipose tissue and increased FA flux to the liver, 26% were from hepatic DNL and 15% were from the diet.^[@bibr25-1098612X19857853]^ Hepatic DNL contributes significantly to FA accumulation in the liver of subject with NAFLD.

The development of hepatic lipidosis has been investigated in the American mink, as a model of NAFLD.^[@bibr12-1098612X19857853],[@bibr13-1098612X19857853]^ In the American mink, food deprivation for 3 days was adequate to induce hepatic lipidosis, with liver fat percentage increasing twice in the fasted group vs the control group. The liver steatosis in the initial days of fasting was secondary to the flux of FAs from extensive peripheral lipolysis from the visceral adipose tissue.^[@bibr12-1098612X19857853],[@bibr13-1098612X19857853]^ In the following days, the percentage of liver lipid accumulation increased dramatically to the end of the 7-day fasting period. Significant increases were observed in the levels of mRNA encoding for acetyl-CoA carboxylase 1 (*ACC-1*) and *FASN* after 5--7 days of fasting compared with non-fasted mink. It was concluded that hepatic DNL could have further exacerbated liver fat accumulation in fasted minks and that 5--7 days of fasting appeared to be the critical time period for this to develop. Although *SREBP-1c* was not measured in this study, the higher expression of *FASN* and *ACC-1*, and the higher hepatic palmitate and MUFA concentrations, suggested that the gene expression of the key enzymes for DNL was increased. Feeding the minks for 28 days after the end of the fasting period allowed the relative expression of *ACC-1* and *FASN* to return to pre-fasting levels.^[@bibr13-1098612X19857853]^

In a model of a diet-induced overweight state in cats, lipogenic gene expression (*SREBP-1c, FASN* and ATP citrate lyase \[*ACLY*\]) in lipid sensitive tissue, that is liver, subcutaneous and abdominal adipose tissue, has been evaluated and compared with lean animals.^[@bibr46-1098612X19857853]^ As already demonstrated in humans, a positive energy imbalance due to overnutrition and obesity can activate *SREBP-1c* and other secondary lipogenic gene expressions, enhancing lipogenesis in adipose and liver tissues contributing to liver steatosis.^[@bibr18-1098612X19857853],[@bibr19-1098612X19857853],[@bibr21-1098612X19857853]^ In the overweight cats, mRNA expression of *SREBP-1c* and ATP citrate lyase were markedly decreased in liver tissue, whereas *FASN* expression remained similar to that of control cats. Abdominal *SREBP-1c* mRNA expression was markedly lower in abdominal subcutaneous and higher in omental adipose tissues of overweight cats than in control cats. The conclusion of this study was that in an overweight cat model DNL does not occur in the liver, but it occurs in the visceral adipose tissue.^[@bibr46-1098612X19857853]^ This supports the finding of Hall et al,^[@bibr40-1098612X19857853]^ that the origin of the enhanced hepatic TGs in cats with FHL is the visceral adipose tissue and not the liver.

Our study has some limitations. Although the collection process of healthy liver tissue (ie, needle biopsies) and of FHL livers (ie, post-mortem wedge material) were different, there are no indications that the biopsy technique itself could have caused differences in relative mRNA expression levels.

In order to validate the qRT-PCR data, the reduced mRNA level needs to be confirmed by quantitative measurement at the protein level. This confirmation step is currently hampered by the very low hepatic expression of *SREBF1* together with the lack of validated antibodies for *SREBF1* in feline tissues. Interestingly, the downregulation of *SREBF1*, as observed here in vivo, is similar to the downregulation observed in three-dimensional feline liver organoids cultured in vitro under FA overload, lending credence to the robustness of the qRT-PCR measurements.^[@bibr44-1098612X19857853]^

Conclusions {#section13-1098612X19857853}
===========

The downregulation of *SREBF1* in the liver tissue of cats with FHL does not support the hypothesis that DNL in the liver is an important pathway of FA accumulation in FHL. As cats with hepatic lipidosis have an increased concentration of palmitate and MUFAs vs healthy cats in their liver and visceral adipose tissue, DNL in FHL most likely occurs in the abdominal adipose tissue. Subsequently, the de novo synthetised MUFAs are transported from the adipose tissue to the liver, where they contribute to fat overload in FHL.
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